RO6889678 / Roche - LARVOL DELTA

Simultaneous Assessment of Clearance, Metabolism, Induction and Drug-Drug Interaction Potential using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor. (PubMed, J Pharmacol Exp Ther) - "...The approach is exemplified in the case of (3S)-4-[[(4R)-4-(2-Chloro-4-fluorophenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid RO6889678, a novel inhibitor of HBV with a complex absorption, distribution, metabolism, and excretion (ADME) profile...Furthermore, we report on the first evaluation of in vitro pharmacokinetics studies using HBV-infected HepatoPacco-cultures. Thus, long-term liver models have great potential as translational research tools exploring pharmacokinetics of novel drugs in vitro in health and disease."

Journal • Preclinical